Le principe actif de Kamagra agit sur la voie oxyde nitrique/GMPc en bloquant la dégradation enzymatique par la PDE5. Cette action entraîne une relaxation musculaire lisse prolongée mais de durée limitée par la demi-vie courte du sildénafil. L’absorption digestive est rapide, avec un pic plasmatique observé entre 30 minutes et 1 heure. Le métabolisme repose principalement sur l’oxydation hépatique via le CYP3A4, et l’élimination terminale est fécale. Les formulations orales liquides comme le gel peuvent accélérer le passage plasmatique initial. Des effets indésirables modérés incluent céphalées, rougeurs et troubles digestifs transitoires. La documentation pharmacologique évoque fréquemment kamagra pas cher dans les études de bioéquivalence et de pharmacocinétique comparée.

Genindex-prodindex.xls

SUBJECT TITLE
VOLUME NO
ACETAZOLAMIDE TABS - FUNGAL CONTAMINATION ADMINISTRATION -RESPONSIBILITIES FOR SAFE ADRENALINE - PACKAGING OF PRE-FILLED SYRINGES ALFACALCIDOL - LABELLING AND OVERDOSE INCIDENTS ALUMINIUM CONTAMINATION OF CALCIUM GLUCONATE AMPHOTERICIN - SOLUTION ON RECONSTITUTION ANAESTHETIC MACHINES AND OXYGEN ANALYSERS ASCORBIC ACID - NON PL TABLETS POOR QUALITY ASEPTIC PREPARATION - FINAL CHECKING ISSUES ASPARAGINASE - PARTICLES AFTER RECONSTITUTION ATROPHINE - ADRENALINE SYRINGE IN CRASH BOX BENADRYL - CONFUSION OF ACTIVE INGREDIENTS BETAMETHASONE - INCOMPATIBILITY WITH COAL TAR BETAMETHASONE EYE DROPS - USE AFTER OPENING BRAND NAMES - CONFUSION OF ACTIVE INGREDIENTS BUDESONIDE (PULMICORT RESPULES) LABELLING CANCER CHEMOTHERAPY: FOR BETTER FOR WORSE REPORT CHLORMETHIAZOLE SYRUP - STORAGE TEMPERATURE CIPROFLOXACIN SUSPENSION - LABELLING ISSUES CLINICAL TRIALS - IMPLEMENTATION OF EC DIRECTIVE CLINOMEL - CONTENTS MIXING BEFORE INTENDED USE CLINOMEL - CONTENTS MIXING BEFORE INTENDED USE CO-CARELDOPA TABS - DOWELHURST PARALLEL IMPORT COLD CHAIN MONITORING/FRIDGE TEMPERATURES COLOMYCIN - SHELF LIFE AFTER RECONSTITUTION COMPLIANCE ISSUES LABELLING & PACKAGING COMPLIMENTARY AND NATURAL HEALTHCARE COUNCIL CONTACT LENS SOLNS - ACANTHAMOEBA KERATITIS COTRIMOXAZOLE - PRECIPITATION OF INJECTION COUNSELLING - CODE OF ETHICS REQUIREMENTS CYCLOPENTOLATE EYE DROPS - PACKAGING PROBLEMS CYCLOPHOSPHAMIDE - RECONSTITUTION DIRECTIONS CYTARABINE INJECTION - STRENGTH CONFUSIONS CYTOTOXIC DRUGS - HEALTH AND SAFETY ISSUES DIPHTHERIA VACCINE - EXPIRY DATE CONFUSION DIPTHERIA & TETANUS VACCINE - LABELLING DISCONTINUED MEDICINES - BEST PRACTICE GUIDELINES DOXORUBICIN - DILUENT FOR RECONSITITUTION ERTHROMYCIN SUSPENSION - VOLUME AFTER RECONSTITUTIO ETOMIDATE - POTENTIAL MIX-UP WITH PROPOFOL EXTEMPORANEOUS DISPENSING - YELLOW COVERED DOCUME FLECAINIDE INJ - GLASS FRAGMENTS WHEN AMPS OPENED FLUCLOXACILLIN SYRUP - FAILURE TO DISSOLVE FLUPHENAZONE INJECTION LABELLING CONFUSION FLUROURACIL - MORE REPORTS OF CRYSTAL PRESENT FRESUBIN EASY BAGS - MICROBIAL CONTAMINATION FRESUBIN EASY BAGS - MICROBIAL CONTAMINATION GELOFUSINE - DIFFICULTIES WITH GIVING SETS & LEAKING BAG GEMCITABINE - RECONSTITUTION INSTRUCTIONS GENERICS - MODIFIED RELEASE PREPARATIONS HAZARDS/RISKS IN DISPENSARIES (EDITORIAL) HEARING AID LOOP SYSTEM - N&N HOSPITAL HUMAN IMMUNOGLOBULIN - RECONSTITION PROBLEMS INFUSION BAGS - WATER LOSS DURING STORAGE INFUSIONS - PLASTIC PARTICLES CONTAMINATION INJECTIONS - LABELLING OF SYRINGES IN THEATRES INJECTIONS - PREPARATION IN CLINICAL AREAS INNOVATIONS - ALTERNATIVE TO FREEZE DRYING INTRATHECAL INJECTIONS INVOLVING CHEMOTHERAPY ISOSORBIDE MONONITRATE - LABEL DEFECT/RECALL LABELLING AND PACKAGING - CSM WORKING GROUP LEAFLETS - PILs NOT AVAILABLE FOR SOME PRODUCTS LICENCE ISSUES - IMPORTED DRUGS (EDITORIAL) LIGNOCAINE DENTAL CARTRIDGES - STORAGE REQUIREMENTS MAGNESIUM SULPHATE - EXPRESSION OF STRENGTH MEDICAL DEVICE ALERTS - NEW GUIDANCE DOCUMENT MEDICAL GASES - SAFETY ISSUES WITH MRI EQUIPMENT MEDICAL GASES - TESTING PIPED GAS INSTALLATIONS MEDICAL GASES - YELLOW COLOURATION OF FILTERS MEDICATION ERRORS - LEARNING FROM MISTAKES MEDICATION ERRORS - LOOK-ALIKE AND SOUND-ALIKE NAMES MEDICATION ERRORS - MICROGRAM/MILLIGRAM CONFUSION MEDICATION ERRORS - PACKAGING AND LABELLING ISSUES MEDICINE HELPLINE - PETERBOROUGH HOSPITAL MEDROXYPROGESTERONE INJ - EXTRACTABLE VOLUME METHOTREXATE TABLETS - STRENGTH CONFUSION METRONIDAZOLE - CONFUSION OF COMPATIBILITIES METRONIDAZOLE - LABELLING OF SUPPOSITORIES METRONIDAZOLE INJECTION - LABELLING CONFUSION MICRO ORGANISMS - SURVIVAL IN HOSTILE ENVIRONMENTS MITOMYCIN - SHELF LIFE AFTER RECONSTITUTION MITOMYCIN - STABILITY AFTER RECONSTITUTION NHS 50TH ANNIVERSARY - PATIENT ENPOWERMENT (EDITORIAL NOMENCLATURE - NAME CONFUSION (EDITORIAL) NORADRENALINE - LABELLING OF IMPORTED INJECTION NOSOCOMIAL INFECTION AND CIVAS (EDITORIAL) ONCOLOGY PHARMACY & CHEMOTHERAPY STANDARDISATION ORGANOPHOSPHATE POISONING - PRALIDOXIME MESYLYTATE OVERLABELLING - OBSCURING ESSENTIAL INFORMATION PAPWORTH HOSPITAL - QUALITY IMPROVEMENT INITIATIVES PATIENT PERCEPTIONS - SERVICE QUALITY (EDITORIAL) PENTOSTAM, PENTOSAN, PENTOSTATIN NAME CONFUSION PHENOL INJECTION IN ALMOND OIL - LABEL ISSUE POTASSIUM CHLORIDE SOLN - DILUTION REQUIREMENTS POVIDONE IODINE VAGINAL GEL - APPLICATOR PROBLEMS PRESCRIBING FOR CHILDREN - OFF-LABEL ISSUES PRESCRIPTION WRITING - LEGIBILITY/COMPUTERS PROCHLORPERAZINE - TABLET COLOUR VARIATION PRODUCT LICENCES/MARKETING AUTHORISATIONS NUMBERS PROPOFOL - INCOMPATIBILITY WITH VYGON LINES QUALITY MATTERS 100TH EDITION (EDITORIAL) SAFETY - RSI AND OTHER OCCUPATIONAL HAZARDS SALBUTAMOL - LABELLING OF BLOW FILL SEAL SODIUM CHLORIDE - NORMOSOL SACHETS - CONCENTRATION SODIUM CHLORIDE INJECTION - EXPRESSION OF STRENGTH SODIUM CHLORIDE INJECTION - EXPRESSION OF STRENGTH SODIUM CHLORIDE UROTAINERS - USER PROBLEMS STANDARDS - PERVERSE INCENTIVES (EDITORIAL) STAVUDINE ORAL SOLUTION - LABELLING CONFUSION STERILE MANUFACTURE/PREPARATION OCCUPATIONAL SYRINGE HUBS - LEAKING MULTI-ADD (BRAUN) BRAND TEICOPLANIN - PRECIPITATION OF RECONSTITUTED INJECTION TEICOPLANIN - STABILITY OF RECONSTITUTED INJECTION TPN - ALGORITHM FOR FORMULATION STABILITY TPN - INTRAVENOUS CATHETERS WITH NEONATES UNLICENSED MEDICINES - LOCAL TRUST POLICIES UNLICENSED MEDICINES - PATIENT AWARENESS ISSUES UNLICENSED MEDICINES PATIENT AWARENESS OF STATUS VALIDATION, CHANGE CONTROL & CAPACITY PLANNING VERIFICATION OF CHEMOTHERAPY PRESCRIPTIONS VINCA ALKALOIDS - DOH REPORT FOLLOWING NOTTINGHAM FAT VINCRISTINE ADMINISTRATION GUIDELINES (EDITORIAL) VIPER VENOM ANTISERUM - DOSE INSTRUCTIONS

Source: http://www.nhsped.uea.ac.uk/assets/v2/documents/genindex-prodindex.pdf